Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
INO Inovio Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: INO
Price (delayed)
$1.88
Market cap
$68.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.19
Enterprise value
$40.3M
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO
Highlights
INO's EPS is up by 42% year-on-year and by 19% since the previous quarter
INO's net income is up by 23% year-on-year and by 10% since the previous quarter
The gross profit has dropped by 61% year-on-year but it rose by 30% since the previous quarter
INO's revenue has dropped by 61% year-on-year but it is up by 30% since the previous quarter
The equity has contracted by 46% YoY and by 25% from the previous quarter
INO's quick ratio is down by 45% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of INO
Market
Valuations
Earnings
Shares outstanding
36.67M
Market cap
$68.95M
Enterprise value
$40.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
256.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
142.37
Revenue
$283,099
Gross profit
$283,099
Operating income
-$105.96M
Net income
-$96.48M
EBIT
-$96.48M
EBITDA
-$93.37M
Free cash flow
-$102.64M
Per share
Balance sheet
Liquidity
EPS
-$3.19
EPS diluted
-$3.19
Free cash flow per share
-$2.66
Book value per share
$1.4
Revenue per share
$0.01
TBVPS
$2.26
Total assets
$87.27M
Total liabilities
$36.02M
Debt
$11.27M
Equity
$51.25M
Working capital
$44.57M
Debt to equity
0.22
Current ratio
2.63
Quick ratio
2.55
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
-32,979.7%
Gross margin
100%
Net margin
-34,079.6%
Operating margin
-37,430.2%
Return on assets
-87.4%
Return on equity
-133.1%
Return on invested capital
-179.1%
Return on capital employed
-160.9%
Return on sales
-34,079.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INO stock price
How has the Inovio Pharmaceuticals stock price performed over time
Intraday
-2.08%
1 week
6.82%
1 month
6.21%
1 year
-83.54%
YTD
2.73%
QTD
15.34%
Financial performance
How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$283,099
Gross profit
$283,099
Operating income
-$105.96M
Net income
-$96.48M
Gross margin
100%
Net margin
-34,079.6%
The company's operating margin has shrunk by 104% YoY but it rose by 27% QoQ
Inovio Pharmaceuticals's net margin has shrunk by 96% YoY but it has increased by 31% QoQ
The gross profit has dropped by 61% year-on-year but it rose by 30% since the previous quarter
INO's revenue has dropped by 61% year-on-year but it is up by 30% since the previous quarter
Price vs fundamentals
How does INO's price correlate with its fundamentals
Growth
What is Inovio Pharmaceuticals's growth rate over time
Valuation
What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.35
P/S
256.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
142.37
INO's EPS is up by 42% year-on-year and by 19% since the previous quarter
The stock's price to book (P/B) is 59% less than its 5-year quarterly average of 3.3 and 10% less than its last 4 quarters average of 1.5
The equity has contracted by 46% YoY and by 25% from the previous quarter
INO's revenue has dropped by 61% year-on-year but it is up by 30% since the previous quarter
The P/S is 37% lower than the last 4 quarters average of 405.4 and 29% lower than the 5-year quarterly average of 359.3
Efficiency
How efficient is Inovio Pharmaceuticals business performance
The company's return on invested capital has shrunk by 100% YoY and by 19% QoQ
INO's return on sales has dropped by 97% year-on-year but it is up by 31% since the previous quarter
INO's ROE is down by 38% YoY and by 3.4% from the previous quarter
INO's return on assets is down by 27% year-on-year
Dividends
What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INO.
Financial health
How did Inovio Pharmaceuticals financials performed over time
The total assets is 142% greater than the total liabilities
INO's current ratio is down by 45% YoY and by 5% QoQ
INO's quick ratio is down by 45% year-on-year and by 6% since the previous quarter
Inovio Pharmaceuticals's debt is 78% lower than its equity
The debt to equity has soared by 57% YoY and by 29% from the previous quarter
The equity has contracted by 46% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.